GSKB Almaz-Antey

JSC GSKB Almaz-Antey named after A.A. Raspletin (Russian: ГСКБ Концерна ПВО „Алмаз-Антей“, former SB-1, 1947–50; KB-1, 1950–66; MKB Strela, 1966–71; TsKB Almaz, 1971–88; NPO Almaz, 1988–2008) is a Soviet/Russian military R&D enterprise founded in 1947. It is the core of the Almaz-Antey holding. Headquarters – Moscow, Leningradsky av., 80.

Since 1955 KB-1 developed such air defence missile systems S-25, S-75, S-125, S-200, S-300, S-400 Triumf, S-300PMU and S-300PMU2, and recently S-350E Vityaz missile system.

Since 30 November 2009 by the decision of the board of directors of Almaz-Antey 4 joint-stock companies were reorganised and joined NPO Almaz to form GSKB joint venture, namely NIEMI, NIIRP, MNIIRE Altair and MNIIPA. GSKB strengthen its position as the head developer of Almaz-Antey holdings, became Head System Design Bureau (Russian: ГСКБ, Головное системное конструкторское бюро).

NIIRP scientific & research center is developing the Joint system of air and ballistic missile defense (Russian: ЕС ЗРО ПВО-ПРО). Earlier, NIIRP successfully developed the A-135 BMD system together with Amur-P multi-channel firing system which were put into operation to protect Moscow on 17 February 1995. Its predecessor also designed by NIIRP, the A-35 and A-35M BMD systems, defended Moscow since 1977.

GlaxoSmithKline

GlaxoSmithKline plc (GSK) is a British pharmaceutical company headquartered in Brentford, London. Established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, GSK was the world's sixth largest pharmaceutical company as of 2015, after Pfizer, Novartis, Merck, Hoffmann-La Roche and Sanofi.Andrew Witty has been the chief executive officer since 2008.

The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index. As of December 2015 it had a market capitalisation of £65 billion, the fifth largest on the London Stock Exchange. It has a secondary listing on the New York Stock Exchange.

GSK's drugs and vaccines earned £21.3 billion in 2013; its top-selling products that year were Advair, Avodart, Flovent, Augmentin, Lovaza and Lamictal. GSK's consumer products, which earned £5.2 billion in 2013, include Sensodyne and Aquafresh toothpaste, the malted-milk drink Horlicks, Abreva for cold sores, Breathe Right nasal strips, Nicoderm and Nicorette nicotine replacements, and Night Nurse, a cold remedy. The company developed the first malaria vaccine, RTS,S, which it said in 2014 it would make available for five percent above cost. Legacy products developed at GSK include several listed in the World Health Organization Model List of Essential Medicines, such as amoxicillin, mercaptopurine, pyrimethamine and zidovudine.